Virtu Financial’s HCW Biologics HCWB Stock Holding History

Virtu Financial’s Portfolio HCWB Stock Details HCWB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,968	Closed	-$17K	–	1867
2026 Q1	$17K	Buy	+7,968	New	+$41.2K	﹤0.01%	1410
2025 Q1	–	Sell	-65	Closed	-$7K	–	1634
2024 Q4	$7K	Buy	+65	New	+$7.58K	﹤0.01%	1412

Other funds holding HCWB

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $142M AUM 51.29% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSWM

Golden State Wealth Management Santa Ana, California $1.1B AUM 27.5% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Virtu Financial's HCWB Position: Q2 2026 in Review

Virtu Financial sold out of HCW Biologics (HCWB) in Q2 2026, closing a stake of 7,968 shares — an estimated $17K sold.

Virtu Financial first reported a position in HCWB in Q4 2024 and held it in 2 quarters. The position peaked at $17K in Q1 2026. 12 funds tracked by Wall St. Rank hold HCWB as of Q2 2026.

Virtu Financial reported no remaining HCW Biologics position as of Q2 2026 after selling out during the quarter.
Virtu Financial sold 7,968 HCW Biologics shares in Q2 2026, an estimated $17K.
Virtu Financial first reported a position in HCW Biologics in Q4 2024 and held it in 2 quarters.
Virtu Financial's HCW Biologics position peaked at $17K in Q1 2026.
12 funds tracked by Wall St. Rank held HCW Biologics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.